NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Diagnostics & Research · USD

Illumina, Inc. (ILMN) Stock Analysis

Illumina, Inc. (ILMN) is a Diagnostics & Research stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ILMN

$282.86

+$14.93 (+5.57%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ILMN with… →

ILMN Key Statistics

As of Oct 21, 2026
Trading
Open
$267.35
Previous Close
$267.93
Day's Range
263.28–286.40
52-Week Range
94.00–309.35
Volume
2.27M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.42
Valuation
Market Cap
$42.71B
P/E Ratio
52.77
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
46.18
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
3.31
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
9.50
EPS (ttm)Profit attributable to each share over the last twelve months.
5.36
Financials (FY)
Revenue (FY)
$4.34B−0.66%
Net Income (FY)
$850.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
18.34%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
151.00M
1-Year Return
+185.83%
Dividend and dates
Earnings Date
October 29, 2026
Avg Volume
2.77M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ILMN closed at $282.86, +185.83% over 1 year.

Illumina, Inc. (ILMN) has a market capitalization of $42.71B.

In fiscal 2025, ILMN reported revenue of $4.34B.

ILMN Stock Return by Calendar Year

Illumina, Inc. (ILMN) 10-year return: what $10,000 became

1 year
$10,000 $28,583
+185.83%
5 years
$10,000 $7,065
−29.35%
10 years
$10,000 $20,506
+105.06%

If you had invested $10,000 in Illumina, Inc. (ILMN) 10 years ago, at the close on October 21, 2016, it would have been worth $20,506 at the close on October 21, 2026: +105.06% in total, +7.45% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+115.66%
2025−1.85%
2024−1.34%
2023−31.14%
2022−46.85%
2021+2.82%
2020+11.53%
2019+10.61%
2018+37.27%
2017+70.64%
2016 (partial year)−23.08%

As of October 21, 2026.

ILMN Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.34B$850.00M19.6%
2024$4.37B−$1.22B−28.0%
2023$4.50B−$1.16B−25.8%
2022$4.58B−$4.40B−96.1%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.34B$2.87B$817.00M$850.00M19.6%
2024$4.37B$2.86B$600.00M−$1.22B−28.0%
2023$4.50B$2.74B−$222.00M−$1.16B−25.8%
2022$4.58B$2.97B$354.00M−$4.40B−96.1%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ILMN Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricILMNDiagnostics & Research medianvs median
P/E52.7737.5940% above
P/S ratio9.505.2382% above
Profit margin18.34%−0.93%19.3 pts above

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Illumina, Inc. (ILMN) at $42.71B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 8,600.

ILMN last closed at $282.86 on October 21, 2026. That is +$14.93 (+5.57%) against the previous close. Over the past 52 weeks the price has ranged from $94.00 to $309.35. The latest close sits 200.91% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.34B. That is −0.66% against the prior fiscal year, when revenue was $4.37B. Net income for the same year was $850.00M. Profit margin runs at 18.34%. That is 19.3 percentage points above the Diagnostics & Research median of −0.93%. Trailing earnings per share are 5.36.

Across the 4 fiscal years on file, revenue moves from $4.58B in 2022 to $4.34B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 52.77 times earnings. That is 40.4% above the Diagnostics & Research median of 37.59. On forward earnings the ratio is 46.18. The PEG ratio, which sets the P/E against expected earnings growth, reads 3.31. Measured against sales, the shares trade at 9.5 times revenue. On price-to-sales that is 81.83% above the Diagnostics & Research median of 5.23. 45 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.42. Annualized volatility over the trailing 10 years is 42.1%. Over the trailing twelve months the total return is +185.83%. Across 10 years the annualized return works out at +7.45%.

Growth & Income

No dividend is on file for ILMN.

2026 is still running; the total return is +115.66% year to date. Across the complete calendar years on file, 2017 returned +70.64% and 2022 returned −46.85%. Of the 9 complete calendar years on file, 5 finished higher.

Peer Comparison

Illumina, Inc. (ILMN) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Illumina, Inc. ILMN $42.71B 52.8
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. Illumina, Inc. trades at a P/E of 52.8.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 IQV

IQVIA Holdings Inc.

$45.53B

 WAT

Waters Corporation

$44.92B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Illumina, Inc.

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers, as well as through life-science distributors. The company has a collaboration with Labcorp Holdings Inc. for the development of oncology treatments through applications of sequencing solutions across the healthcare ecosystem; and strategic collaboration with Integrated DNA Technologies to enable a DRAGEN, secondary analysis pipeline for IDT xGena, FFPE and cfDNA next generation sequencing (NGS) library preparation with custom panels, delivering an integrated, end-to-end solution for somatic oncology research. It also has a data partnership with Center for Data-Driven Discovery in Biomedicine to advance research in pediatric cancer and rare disease. Illumina, Inc. was incorporated in 1998 and is headquartered in San Diego, California.

Visit website →